INTRODUCTION:
=============

Hyperparathyroidism is a disease entity that occurs due to increased secretion of parathyroid hormone (PTH) from parathyroid glands and causes hypercalcemia.[@b1] Secondary hyperparathyroidism is a response to low calcium levels related to hypovitaminosis D. It is well established that there is an inverse relationship between serum 25-hydroxyvitamin D (25-OHD) and serum PTH.[@b2],[@b3] The levels of 25-OHD that lead to a rise in serum PTH are still a matter of debate.[@b4]-[@b6] Reports suggest that not all who are vitamin D insufficient have increased PTH levels.[@b7]-[@b9] It has been suggested that the variability of PTH levels in hypovitaminosis D may be due to concomitant magnesium deficiency.[@b9] Patel et al.[@b10] suggested that glomerular filtration rate is the single most important factor in maintaining PTH levels. Gunnarsson et al.,[@b11] while supporting the kidney function hypothesis, felt that body mass index may play a role in women by blunting the level of PTH and added that in men, insulin-like growth factor 1, smoking, and testosterone levels may do the same.

A diagnosis of secondary hyperparathyroidism will therefore depend on measurement of an insufficient or deficient amount of 25-OHD in association with a rise of PTH. The World Health Organization (WHO) described a serum level of 25- OHD of 20 ng/ml or 50 nmol/l as deficiency[@b12] and a level of 30 ng/ml (75 nmol/l) as normal because at this level, PTH drops down to normal levels.[@b13],[@b14] At present, it is believed that below 30 ng/ml of 25-OHD, the level of PTH should start rising.[@b15]-[@b16]

A review of literature did not reveal any studies correlating PTH levels to the accuracy of 25-OHD levels by different assays; hence, our objective was to determine whether any correlation existed between the true levels of 25-OHD and PTH levels by means of three different assays.

PATIENTS AND METHODS:
=====================

A cross-sectional study was conducted in 200 patients (150 women and 50 men) between January 2011 and December 2012, aged between 18-69 years, attending the outpatient clinics at King Fahd Hospital of the University, Al Khobar, Saudi Arabia. The first 200 patients seen who were not taking vitamin D supplementation were included in the study.

An earlier study had shown that there was wide variation between the three assays tested. -using a 30 ng/ml cut-off, 6%, 9%, and 22% had normal levels of 25-OHD in CLIA, RIA, and HPLC LC-MS, respectively, and showed different levels of hyperparathyroidism.[@b17] Patients' weight, height and results of renal and liver function tests were extracted from the medical charts. Serum calcium, phosphorous, alkaline phosphatase, PTH, and 25-OHD tests were performed. 25-OHD was assessed using chemiluminescence immunoassay (CLIA), radioimmunoassay using Wallac 1470 Gamma Counter, and HPLC-LC.MS (high performance liquid chromatography-liquid chromatography with mass spectrometry). The data were analysed using the Statistical Package for the Social Sciences (SPSS), version 14.0, Chicago, Illinois. Data is presented as a mean ± standard deviation (SD). Mean serum 25-hydroxyvitamin D values with 95% confidence intervals (CI) for each assay were calculated, and a p value of \<0.05 was considered significant. Each was then compared with parathyroid hormone levels and labelled as normal, insufficient, and deficient in 25-OHD as determined by each assay using linear regression analyses for the relationship between age, sex, CLIA, RIA, HPLC-LS.MS and PTH levels and the correlation between PTH and CLIA, RIA, and HPLC-LS.MC.

RESULTS:
========

The mean age was 45.8±15.8 (18-74) years, and calcium level was 2.27±0.15 mmol/l. (range 2.125 to 2.62 mmol/l). Alkaline phosphatase was 88.91±35.94 (34-302) IU, PTH 6.7±3.06 (1.35-21.2) (1.3-6.8 pmol/l). [Table 1](#tbl1){ref-type="table"} gives the demographic data of all the patients. [Table 2](#tbl2){ref-type="table"} gives the comparison of 25-OHD between the three assays. Of the participants, 188 were either insufficient or deficient as shown by CLIA 11.85±6.14 (2-29.6), and 91 (48.4%) of them had secondary hyperparathyroidism 9.48±4.55 pc/l, whereas with HPLC-LC. MS, 156 were either insufficient or deficient, 97 with PTH level of 7.41±4.2. In patientswith insufficiency as shown by HPLC-LC-MS, 13/41 (31.7%) had raised parathyroid hormone.

###### 

Demographic characteristics of the patients

  *Variables*                             Total (n=200)         
  --------------------------------------- --------------------- ------------------------
  Sex                                     50 (25)               150 (75)
  Age (years)                             48.1±17.0 (14-76)     44.8±15.7 (3-80)
  Calcium mmol/L                          2.287±0.21            2.4±0.065
  PO4mg/dl                                3.7±0.6 (2.6-4.9)     4.0±2.9 (1.8-39.0)
  Parathromone (pmol/L)                   7.9±3.5 (3.2-19.8)    6.6±4.2 (1.4-43.9)
  25-OHD (ng/mL)                          13.3±7.2 (2.0-34.6)   14.0±14.0 (3.3-150.0)
  Chemiluminescent immunoassays (ng/mL)   9.2±0.7 (8.3-13.1)    9.6±6.3 (7.9-86.0)
  HPLC-D3 (ng/mL)                         12.4±4.0 (6.0-25.0)   24.7±14.5 (12.0-150.0)

Values are presented as Mean ± SD or n (%); Range in Parenthesis

###### 

25-OHD levels with ≤20 ng/ml as deficiency, 21-29 as insufficiency and normal level as ≥30ng/ml.

  Vitamin D Levels   Normal   Insufficiency   Deficiency                     
  ------------------ -------- --------------- ------------ -------- -------- --------
                     Normal   Raised          Normal       Raised   Normal   Raised
  CLIA               12       0               18           4        80       86
  RIA                18       0               6            22       52       102
  HPLC               44       0               13           28       0        115

All patients with vitamin D deficiency as diagnosed by HPLC-LC.MS had secondary hyperparathyroidism. Linear regression analyses for the relationship between the age, sex, BMI, creatinine level, and alkaline phosphatase, CLIA, RIA, and LC. MS against PTH levels are given in [Table 3](#tbl3){ref-type="table"}. It is clear from [Table 3](#tbl3){ref-type="table"} illustrating linear regression that the beta coefficient of the regression of PTH on RIA is significant at beta=0.160, t=2.341, p\<0.05 and HPLC-LC.MS beta=-0.228, t=-3.714, p\<0.001 with r square of 0.151, and that there is a significant association between PTH and RIA and HPLC-LC. MS.

###### 

Linear regression analyses for the relationship between the age, sex, BMI, Creatinine level and Alkaline Phosphatase, CLIA, RIA and HPLC-LC.MS against the Parathromone.

                                  **Unstandardized Coefficients**   **R-square**   **F-value**   **t**   **P-value**   
  ------------------------------- --------------------------------- -------------- ------------- ------- ------------- ----------
  (Constant)                      7.965                             1.767                                4.509         .000
  AGE                             .018                              .017                                 1.052         .294
  SEX                             -.022                             .699                                 -.031         .975
  BMI                             .013                              .015                                               
  Creatinine level                .011                              .010           0.151         5.551                 
  Alkaline Phosphatase            .011                              008            1.361         .175                  
  Chemiluminescent immunoassays   -.050                             .050                                 -.995         .321
  Radioimmunoassay                .160                              .068                                 2.341         **.020**
  High-pressure liquid                                                                                                 
  chromatography-D3               -.228                             .061                                 -3.714        **.000**

Dependent Variable: PARATHROMONE

We further performed Pearson correlation analysis, showing the relationship between the variables, and the table depicts that PTH has a significant negative relationship with RIA (r = -0.247, p \<0.001), HPLC-LC.MS (r=-0.322, p\<0.001) and that RIA has a positively significant relationship with HPLCLC. MS (r=0.946, p\<0.001). Hence, there is a significant relationship between PTH and RIA, HPLC-LC.MS ([Table 4](#tbl4){ref-type="table"}).

###### 

Correlation between Parathormone and CLIA, RIA, HPLC-LC.MS.

                               **CLIA**   **RIA**     **HPLC**
  ------------------ --------- ---------- ----------- -----------
  **PARATHROMONE**   r-value   -.054      **-.247**   **-.322**
  P-value            .451      .000       .000        
  **CLIA**           r-value   1          .045        .032
  P-value                      .523       .654        
  **RIA**            r-value              1           **.946**
  P-value                                 .000        
  **HPLC**           r-value                          1
  P-value                                             

DISCUSSION
==========

Our study shows that there is a definite association between hyperparathyroidism and 25-OHD levels, but the assay chosen will influence the level of 25-OHD and hence classification of a patient as vitamin D deficient or insufficient. All patients with normal 25-OHD as assessed by all three assays, CLIA, RIA, and HPLC-LC.MS, had normal PTH levels. In patients with deficiency, PTH was raised in 51.8%, 66.23%, and 100% as assessed by CLIA, RIA, and HPLC-LC.MS, respectively. Our study further supports others which indicate the inverse relationship of 25-OHD and PTH,[@b2],[@b3],[@b18],[@b19] even though Kilicarslan, Cenoliaslan, and Gezgen[@b20] reported that in their study, that over 75% of the vitamin D-deficient patients had normal levels of PTH. In another study of a small number of patients by Elsammak et al.[@b21] PTH did not correlate with serum vitamin D level in either of the genders.

Studies have reported different influencing factors that raise PTH level and are not related directly to the level of 25-OHD. Moreover, Vuceljić et al[@b22] found that a raised PTH level is not seen in all patients with 25-OHD deficiency. In their study, only 25.3% with 25-OHD deficiency had raised PTH. On the other hand, Arabi et al[@b23] stated that the negative relationship between 25-OHD and PTH is modulated by age but not gender. Secondly, reports from the Middle Eastern countries indicate that an inverse relationship exists between vitamin D and PTH levels in all age groups.[@b24],[@b25] In this study, we have noticed that the relationship between PTH and 25-OHD existed in all age groups and that gender does play a role. Our male population had significantly higher PTH levels when compared to the female population (7.9±3.5 versus 6.6±4.2 P\<0.039), while the 25-OHD level was 13.3±7.2 versus 14.0±14.0 ng/ml (P\<0.723), respectively.

Ardawi et al[@b26] in their study found that the inverse relationship between 25-OHD and PTH was not influenced by the level of 25-OHD and could not pinpoint the levels of 25-OHD at which PTH levels will plateau. From the studies cited above, it appears that various factors play a role in raising the PTH, but we believe that one important factor that increases PTH is a level of 25-OHD below 20ng/ml. The inconsistency of other reports of the relationship of PTH and 25-OHD may be due to the inaccuracy of the assay used in the assessment.

Our study has limitations as a small cohort group, and differences in the gender comparison were unequal; secondly, we also need to compare results from different PTH assays, as well. The strength of our study is that we have tried for the first time to check the vitamin D levels with three different assays and simultaneously correlate PTH levels with different assays. The results of this study, we believe, should give a direction for future studies to correlate PTH levels with 25- OHD with a properly calibrated assay.

In conclusion, we found that serum PTH levels are normal with all 25-OHD assays of ≥30ng/ml, while issues lie in the accurate measurement of insufficiency and deficiency of 25-OHD. With HPLC-LC.MS, the gold standard to assess 25-OHD, all deficient patients had a raised PTH, while other assays showed normal PTH.
